Oral Delivery of Mycobacterium bovis BCG in a Lipid Formulation Induces Resistance to Pulmonary Tuberculosis in Mice-Reference-Cited by-同舟云学术

Oral Delivery of Mycobacterium bovis BCG in a Lipid Formulation Induces Resistance to Pulmonary Tuberculosis in Mice

Published:2003-01 Issue:1 Volume:71 Page:101-108
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Aldwell Frank E.¹,Tucker Ian G.²,de Lisle Geoffrey W.³,Buddle Bryce M.³

Affiliation:

1. Department of Microbiology

2. School of Pharmacy, University of Otago, Dunedin

3. AgResearch Wallaceville, Upper Hutt, New Zealand

Abstract

ABSTRACT A lipid-based formulation has been developed for oral delivery of Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine. The formulated M. bovis BCG was fed to BALB/c mice to test for immune responses and protection against M. bovis infection. The immune responses included antigen-specific cytokine responses, spleen cell proliferation, and lymphocyte-mediated macrophage inhibition of M. bovis . Oral delivery of formulated M. bovis BCG to mice induced strong splenic gamma interferon levels and macrophage inhibition of virulent M. bovis compared with results with nonformulated M. bovis BCG. Formulated oral M. bovis BCG significantly reduced the bacterial burden in the spleen and lungs of mice following aerosol challenge with virulent M. bovis . Our data suggest that oral delivery of formulated M. bovis BCG is an effective means of inducing protective immune responses against tuberculosis. Lipid-based, orally delivered mycobacterial vaccines may be a safe and practical method of controlling tuberculosis in humans and animals.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.71.1.101-108.2003

Reference44 articles.

1. Aldwell, F. E., D. L. Keen, V. C. Stent, A. Thomson, G. F. Yates, G. W. de Lisle, and B. M. Buddle. 1995. Route of BCG administration in possums affects protection against bovine tuberculosis. N. Z. Vet. J.43:356-359.

2. Aldwell, F. E., A. Pfeffer, G. W. de Lisle, G. Jowett, J. Heslop, D. Keen, A. Thomson, and B. M. Buddle. 1995. Effectiveness of BCG vaccination in protecting possums against bovine tuberculosis. Res. Vet. Sci.58:90-95.

3. Aldwell, F. E., D. N. Wedlock, and B. M. Buddle. 1996. Bacterial metabolism, cytokine mRNA transcription and viability of bovine alveolar macrophages infected with Mycobacterium bovis BCG or virulent M. bovis. Immunol. Cell Biol.74:45-51.

4. Barletta, R. G., B. Snapper, J. D. Cirillo, N. D. Connell, D. D. Kim, W. R. Jacobs, and B. R. Bloom. 1990. Recombinant BCG as a candidate oral vaccine vector. Res. Microbiol.141:931-939.

5. Brewer, T. F. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis.31(Suppl. 3):S64-S67.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines;Frontiers in Immunology;2023-08-11

2. Imprinting of Gut-Homing Receptors on Mtb-Specific Th1* Cells Is Associated with Reduced Lung Homing after Gavage BCG Vaccination of Rhesus Macaques;mBio;2023-04-25

3. Prime Vaccination with Chitosan-Coated Phipps BCG and Boosting with CFP-PLGA against Tuberculosis in a Goat Model;Animals;2021-04-08

4. Survival of Mycobacterium bovis BCG oral vaccine during transit through a dynamic in vitro model simulating the upper gastrointestinal tract of badgers;PLOS ONE;2019-04-19

5. Searching For Calmette - Guerin Bacilli in Bone Marrow Specimens of Vaccinated Children: A Real-Time PCR;J RES MED DENT SCI;2018